Merial launches their updated ProteqFlu™ range

merial logo

Merial is New Proteqfludelighted to inform you that they are launching their latest updated ProteqFlu™ and ProteqFlu™-TE vaccines in South Africa. This sets a new landmark in the development of horse vaccines to protect against equine influenza (Radford, 2014). ProteqFlu™ and ProteqFlu™-TE are the first equine influenza vaccines globally to fully comply with the latest 2014 OIE recommended EIV strains (OIE, 2015).

The ProteqFlu™ range contains the Richmond 07 strain, as well as protects against the latest Florida sublineage Clade 2 strain, more frequently referred to as the Ohio strain (Radford, 2014). They are also the only equine influenza vaccine to use a recombinant viral vector technology (vCP2242 and vCP3011) which stimulates both humoral and cell-mediated immune responses. This would result in a broad immune response, the ability to overcome maternal derived antibodies, and the ability to differentiate infected from vaccinated animals (DIVA).

Hervé Poulet, Head of BioDevelopment and BioResearch at Merial’s Lyon Laboratory summarises this latest advancement; “Merial has developed this strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases, such as with feline leukaemia, rabies, equine influenza and West Nile virus. For the development of ProteqFlu™, our non-replicative recombinant canarypox vector expressing the EI virus HA is used because of its ability to induce a broad immune response, including a strong cellular immunity which is an essential component in protecting against this highly contagious disease.” (Radford, 2014)

For further information, please contact your local Merial Territory manager or the Merial Helpline:

0860 637 425

New Proteqflu

 

References: OIE (2015). Equine influenza: OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition. OIE Headquarters, 6 March 2015. Information last retrieved on 11-02-2016 from http://www.oie.int/our-scientific-expertise/specific-information-and-recommendations/equine-influenza/Radford, L. (2014) . From Pasteur to Proteflu: Latest Advances in Equine R&D. Equine Veterinary Product News. Information last retrieved 11-02-2016 from http://www.ev-pn.com/index.php/news/products-and-services/item/311-from-pasteur-to-proteq-latest-advances-in-equine-rd

Proteqflu™-Te: G3436 (Act 36/1947). Influenza A/equi-2/Ohio/03 recombinant Canarypox virus (vCP2242) and Influenza A/equi-2/Richmond/1/07 recombinant Canarypox virus (vCP3011) and Clostridium tetani toxoid. Indications: Immunisation of horses 4 months and older against equine influenza to reduce clinical signs and virus excretion after infection and against tetanus to prevent mortality. Onset of immunity: 14 days after primary vaccination course. Duration of immunity: 5 months after vaccination course and 1 year after 3rd vaccination. Dosage: 1ml im in the neck region. Primary vaccination course: 1st inj from 5-6 months of age. 2nd inj: 4-6 weeks later. Revacc: 5 months later followed by booster injections for tetanus every 2 years. Proteqflu™: G3435 (Act 36/1947). Influenza A/equi-2/Ohio/03 recombinant Canarypox virus (vCP2242) and Influenza A/equi-2/Richmond/1/07 recombinant Canarypox virus (vCP3011). Indications: Immunisation of horses 4 months and older against equine influenza to reduce clinical signs and virus excretion after infection. Onset of immunity: 14 days after primary vaccination course. Duration of immunity: 5 months after vaccination course and 1 year after 3rd vaccination. Dosage: 1ml im in the neck region. Primary vaccination course: 1st inj from 5-6 months of age. 2nd inj: 4-6 weeks later. Revacc: 5 months later followed by annual booster injections.

 

Sorry, comments are closed for this post.

  • Secured Payments
  • Mastercard
  • Visa
  • instant-eft
  • Payfast